View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 12, 2021

The accelerating use of virtual trials – have your say in our survey

Have your say in GlobalData’s survey on the state of decentralised and virtual clinical trials during Covid-19 and beyond.

By Chris Lo

Take part in GlobalData’s decentralised clinical trials survey here.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Since early March 2020, a significant number of companies, including sponsors, collaborators, and clinical research organizations (CROs) began announcing disruptions to planned and ongoing clinical trials as the reality of pandemic-related lockdowns began to set in.

Disruptions included delaying the initiation of planned trials or withdrawing them completely, suspending enrolment of ongoing trials, or terminating these trials altogether.

Covid-19 lockdowns and social distancing measures caused significant disruption to clinical trials and accelerated the use of decentralised or virtual trials. These clinical trials allow the collection of safety and efficacy data from study participants by using a range of digital technologies that require a minimum number of site visits. These trial designs incorporate supporting technologies such as telemedicine, wearable devices, eConsent, electronic clinical outcome assessments and electronic health records.

Your view

GlobalData is conducting a survey to gauge the state of decentralized/virtual clinical trials along with the impact the COVID-19 pandemic on clinical trials. We are seeking the opinions of respected industry professionals to participate in a short 5-7 minute survey.

Upon completion of the online questionnaire, respondents will also gain access to a summary of the report findings on project completion.

Expanding capabilities

Over the past 18 months, many leading CROs and eConsent software providers have expanded their capabilities in response to the growing demand for these virtual services. Several specialist virtual trial providers have emerged in recent years and attracted considerable attention during the pandemic. Companies that had not considered the decentralised model before had no option but to rapidly implement new technologies and procedures to maintain business continuity.

Covid-19 has brought on a digital transformation in the clinical trials landscape, accelerating technological advancements, prompting regulatory relaxations, encouraging the evolution of CROs into virtual trial providers and rewarding an increased focus on patient-centricity. These ongoing trends will continue to boost the movement towards decentralised and virtual clinical trials.

However, this transition won’t be entirely smooth. There remain concerns related to data integrity and privacy, lack of access to suitable devices or high-speed internet, regulatory ambiguity, interoperability between systems, lack of buy-in from stakeholders and high set-up costs, which could all challenge the speed of the uptake.

Have your say here.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU